| Patent Number |
Title Of Patent |
Date Issued |
| 5912228 |
Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
June 15, 1999 |
| Improved therapeutic compositions having enhanced anti-microbial activity comprising a bactericidal/permeability-increasing (BPI) protein product and an bactericidal-activity enhancing polyoxyethylene block copolymer surfactant (poloxamer) surfactant or a bacterial and fungal growth- |
| 5891618 |
Method for quantifying LBP in body fluids |
April 6, 1999 |
| The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject. |
| 5888973 |
Anti-chlamydial uses of BPI protein products |
March 30, 1999 |
| The present invention relates to methods for treating chlamydial infection comprising administering to a subject suffering from a chlamydial infection a bactericidal/permeability-inducing (BPI) protein product. |
| 5869619 |
Modified antibody variable domains |
February 9, 1999 |
| Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified |
| 5858974 |
Anti-fungal peptides |
January 12, 1999 |
| The present invention relates generally to anti-fungal peptides derived from or based on Domain III (amino aids 142-169) of bactericidal/permeability-increasing protein (BPI) and in vivo or in vitro uses of such peptides. |
| 5856438 |
Biologically active peptides from functional domains of bactericidal/permeability-increasing pro |
January 5, 1999 |
| The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the |
| 5856302 |
Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
January 5, 1999 |
| Improved therapeutic compositions, methods and uses of bactericidal/permeability-increasing protein (BPI) products involve use of dimeric forms of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred formulations include 50 percent or more by |
| 5854214 |
Therapeutic uses of bactericidal/permeability increasing protein products |
December 29, 1998 |
| The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administratio |
| 5851802 |
Methods for recombinant microbial production of fusion proteins and BPI-derived peptides |
December 22, 1998 |
| The present invention relates to methods and materials for the recombinant microbial production of fusion proteins and peptides derived from or based on Domain I (amino acids 17-45), Domain II (amino acids 65-99) and Domain III (amino acids 142-169) of bactericidal/permeability-increasin |
| 5846818 |
Pectate lyase signal sequence |
December 8, 1998 |
| The invention is directed to the pectate lyase B secretion signal and its use to express operably linked sequences in bacterial hosts. |
| 5843685 |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
December 1, 1998 |
| The invention is directed to a chimeric immunoglobulin that recognizes the human tumor antigen bound by antibody ING-1, its production, and use. |
| 5837678 |
Therapeutic uses of bactericidal/permeability increasing protein products |
November 17, 1998 |
| The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administratio |
| 5837491 |
Polynucleotides encoding gelonin sequences |
November 17, 1998 |
| The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transform |
| 5827816 |
Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions con |
October 27, 1998 |
| Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue |
| 5821123 |
Modified antibody variable domains |
October 13, 1998 |
| Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified |
| 5821064 |
Method of screening for an active inflammatory state by determining the concentration of extrace |
October 13, 1998 |
| The present invention provides a method for quantifying the presence of extracellular BPI in body fluids including blood in a subject comprising conducting a BPI immunoassay on body fluid sample obtained from said subject. |
| 5807818 |
Therapeutic uses of bactericidal/permeability increasing protein (BPI) protein products |
September 15, 1998 |
| The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administratio |
| 5804367 |
Method for quantifying LBP in body fluids |
September 8, 1998 |
| The present invention provides a method for quantifying the presence of extracellular LBP in body fluids including blood in a subject comprising conducting an LBP immunoassay on plasma obtained from said subject. |
| 5783561 |
Anti-gram-positive bacterial methods and materials |
July 21, 1998 |
| The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms |
| 5770561 |
Method for potentiating BPI protein product bactericidal activity by administration of LBP prote |
June 23, 1998 |
| The present invention provides methods of potentiating the gram-negative bactericidal activity of BPI protein products by means of administering LBP protein products. |
| 5770196 |
Modified antibody variable domains and therapeutic uses thereof |
June 23, 1998 |
| Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified |
| 5766886 |
Modified antibody variable domains |
June 16, 1998 |
| Methods are described for identifying the amino acid residues of an antibody variable domain which may be modified without diminishing the native affinity of the domain for antigen while reducing its immunogenicity with respect to a heterologous species and for preparing so modified |
| 5763567 |
Biologically active peptides from funcional domains of bactericidal/permeability-increasing prot |
June 9, 1998 |
| The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the |
| 5756699 |
Immunotoxins comprising ribosome-inactivating proteins |
May 26, 1998 |
| The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transform |
| 5756464 |
Therapeutic uses of BPI protein products in humans with hemmorhage due to trauma |
May 26, 1998 |
| Methods and materials for the treatment of humans suffering from hemorrhage due to trauma are provided, in which therapeutically effective amounts of BPI protein products are administered. |
| 5753620 |
Human therapeutic uses of BPI protein products |
May 19, 1998 |
| Disclosed are methods for treatment of humans exposed to bacterial endotoxin in circulation by administration of bactericidal/permeability-increasing (BPI) protein products. Serologically and hematologically verifiable alleviation of endotoxin mediated increases in circulating cytoki |
| 5744580 |
Immunotoxins comprising ribosome-inactivating proteins |
April 28, 1998 |
| The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPS) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transform |
| 5741779 |
Antithrombotic materials and methods |
April 21, 1998 |
| Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered. |
| 5733872 |
Biologically active peptides from functional domains of bactericidal/permeability-increasing pro |
March 31, 1998 |
| The present invention provides peptides having an amino acid sequence that is the amino acid sequence of a human bactericidal/permeability-increasing protein (BPI) functional domain or a subsequence thereof, and variants of the sequence or subsequence thereof, having at least one of the |
| 5731415 |
Lipopolysaccharide binding protein derivatives |
March 24, 1998 |
| Disclosed are novel biologically active lipopolysaccharide binding protein (LBP) derivatives including LBP derivative hybrid proteins which are characterized by the ability to bind to and neutralize LPS and which lack the CD14-mediated immunostimulatory properties of holo-LBP. |
| 5721108 |
Chimeric antibody with specificity to human B cell surface antigen |
February 24, 1998 |
| The present invention relates to a chimeric antibody molecule comprising two heavy chains and two light chains, each of the chains comprising a variable region and a human constant region, said antibody having specificity for the antigen bound by the 2H7 murine monoclonal antibody. T |
| 5703038 |
Therapeutic uses of bactericidal-permeability-increasing protein dimer products |
December 30, 1997 |
| Improved therapeutic uses of bactericidal/permeability-increasing protein (BPI) involve use of BPI protein product formulations in the form of physiologically stable dimeric associations of BPI protein product monomers characterized by enhanced in vivo biological activity. Preferred |
| 5698435 |
Modular assembly of antibody genes, antibodies prepared thereby and use |
December 16, 1997 |
| The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human |
| 5698417 |
Modular assembly of antibody genes, antibodies prepared thereby and use |
December 16, 1997 |
| The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human |
| 5696090 |
Pharmaceutical composition |
December 9, 1997 |
| Polypeptide pharmaceutical compositions having improved stability and resistance to aggregation, particle formation and precipitation comprising a polypeptide pharmaceutical and poloxamer surfactants alone, or in combination with polysorbate surfactants. Preferred polypeptides stabil |
| 5693493 |
Modular assembly of antibody genes, antibodies prepared thereby and use |
December 2, 1997 |
| The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human |
| 5686414 |
Methods of treating conditions associated with corneal transplantation |
November 11, 1997 |
| The present invention provides methods of treating a subject suffering from adverse effects, complications or conditions, associated with or resulting from corneal transplantation, by topical administration of suitable ophthalmic preparations of bactericidal/permeability-increasing (BPI) |
| 5677180 |
Chimeric antibody with specificity to human B cell surface antigen |
October 14, 1997 |
| The present invention relates to a eukaryotic host cell that contains DNA encoding a chimeric antibody molecule comprising two heavy chains and two light chains, each of the chains comprising a variable region and a human constant region, said antibody having specificity for the antigen |
| 5674834 |
Stable bactericidal/permeability-increasing protein products and pharmaceutical compositions con |
October 7, 1997 |
| Disclosed are novel bactericidal/permeability-increasing (BPI) protein products wherein cysteine residue number 132 or 135 is replaced by another amino acid residue, preferably an alanine or serine residue and/or wherein the leucine residue at position 193 is the carboxy terminal residue |
| 5646114 |
Anti-protozoan methods |
July 8, 1997 |
| The present invention relates to methods for treating protozoan infections comprising administering to a subject suffering from protozoan infection, a bacteriocidal/permeability-inducing (BPI) protein product. |
| 5643570 |
BPI-immunoglobulin fusion proteins |
July 1, 1997 |
| Disclosed are novel hybrid fusion proteins comprising at their amino terminus, bactericidal/permeability-increasing protein or a biologically active fragment thereof and, at their carboxy terminus, at least one immunoglobulin heavy chain constant domain useful in treating bacterial i |
| 5639727 |
Therapeutic uses of bactericidal/permeability increasing protein products |
June 17, 1997 |
| The present invention provides therapeutic methods for treatment of conditions including the neutralization of the anti-coagulant activity of heparin, inhibition of angiogenesis, tumor and endothelial cell proliferation, and treatment of chronic inflammatory diseases by administratio |
| 5627153 |
Anti-fungal methods and materials |
May 6, 1997 |
| The present invention relates to methods for treating fungal infection comprising administering to a subject suffering from a fungal infection a bactericidal/permeability-inducing (BPI) protein product. |
| 5621083 |
Immunotoxins comprising ribosome-inactivating proteins |
April 15, 1997 |
| The present invention provides purified and isolated polynucleotides encoding Type I ribosome-inactivating proteins (RIPs) and analogs of the RIPs having a cysteine available for disulfide bonding to targeting molecules. Vectors comprising the polynucleotides and host cells transform |
| 5618920 |
Modular assembly of antibody genes, antibodies prepared thereby and use |
April 8, 1997 |
| The invention relates to the secretion of heavy chain immunoglobulin fragments and light chain immunoglobulins from prokaryotic hosts using a prokaryotic secretion signal peptide wherein the heavy chain fragments and light chains are capable of associating to form an antigen binding |
| 5595898 |
Modular assembly of antibody genes, antibodies prepared thereby and use |
January 21, 1997 |
| The invention relates to cDNA genetic sequences, vehicles containing same as well as hosts transformed therewith, for the production of chimeric immunoglobulin molecules, functional fragments thereof and immunoglobulin derivatives exhibiting novel functional properties comprising human |
| 5578572 |
Anti-gram-positive bacterial methods and materials |
November 26, 1996 |
| The present invention relates to methods of treating gram-positive bacterial infections by administration of a BPI protein product alone, or in combination with an antibiotic. BPI protein product alone has a bactericidal or growth inhibitory effect on selected gram-positive organisms |
| 5578568 |
Method of treating conditions associated with intestinal ischemia/reperfusion |
November 26, 1996 |
| The present invention provides methods of treating adverse physiological effects associated with intestinal ischemia reperfusion by administering to a subject suffering from the effects of intestinal ischemia reperfusion an effective amount of a BPI protein product. |
| 5576195 |
Vectors with pectate lyase signal sequence |
November 19, 1996 |
| The invention relates to DNA coding for a pectate lyase signal peptide which has been inserted into plasmids to create secretion vectors which are capable of producing a chosen protein by directing transport across the bacterial membrane. The secretion vectors have been used to secrete |
| 5576184 |
Production of chimeric mouse-human antibodies with specificity to human tumor antigens |
November 19, 1996 |
| Gene expression elements and their use in production of chimeric antibodies with human constant regions and murine variable regions, and mouse human chimeric antibodies having specificity to human tumor cells, methods of their production, and their use. |
